<DOC>
	<DOCNO>NCT01891344</DOCNO>
	<brief_summary>The purpose study determine patient ovarian , fallopian tube , primary peritoneal cancer best respond treatment rucaparib .</brief_summary>
	<brief_title>A Study Rucaparib Patients With Platinum-Sensitive , Relapsed , High-Grade Epithelial Ovarian , Fallopian Tube , Primary Peritoneal Cancer ( ARIEL2 )</brief_title>
	<detailed_description>Rucaparib orally available , small molecule inhibitor poly-adenosine diphosphate [ ADP ] ribose polymerase ( PARP ) develop treatment ovarian cancer associate homologous recombination ( HR ) DNA repair deficiency ( HRD ) . The safety efficacy rucaparib evaluate several Phase 1 Phase 2 study . An oral formulation focus current development effort . Rucaparib currently investigate monotherapy patient cancer associate breast cancer susceptibility gene 1 ( BRCA1 ) BRCA2 mutation . Clinical data PARP inhibitor indicate ovarian cancer patient population beyond germline BRCA ( gBRCA ) mutation may benefit treatment PARP inhibitor . This study define molecular signature HRD ovarian cancer correlate response rucaparib enable selection appropriate ovarian cancer patient treatment rucaparib . The HRD signature base association extent genomic scarring ( downstream consequence HRD ) patient 's tumor observe clinical benefit rucaparib treatment . Genomic scar assess quantify extent loss heterozygosity across tumor genome ( tumor genomic LOH ) . One main advantage detect tumor genomic LOH identify HRD tumor regardless underlie mechanism , include know ( i.e. , BRCA mutation ) unknown genetic mechanism . Once determine , signature prospectively apply ARIEL2 PART 2 ARIEL3 . This Phase 2 study ( ARIEL2 ) also compare archival versus recently collect tumor tissue order validate use archival tumor tissue assessment HRD status ARIEL3 . This study include 2 part : PART 1 ( complete enrollment ) : Evaluation HRD status rucaparib efficacy patient receive â‰¥1 prior platinum-based regimen platinum-sensitive disease PART 2 ( currently enrol ) : Evaluation HRD status rucaparib efficacy patient receive least 3 prior chemotherapy regimen</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Rucaparib</mesh_term>
	<criteria>The following eligibility criterion pertain patient enrol PART 2 study : Inclusion : Have histologically confirm diagnosis high grade serous Grade 2 Grade 3 endometrioid epithelial ovarian , fallopian tube , primary peritoneal cancer Received least 3 prior chemotherapy regimen . Nonchemotherapy regimens maintenance therapy administer single agent treatment count chemotherapy regimen Relapsed/progressive disease confirm CT scan Have biopsiable measurable disease . Note : biopsy optional patient know harbor deleterious gBRCA mutation Have sufficient archival formalinfixed paraffinembedded ( FFPE ) tumor tissue available plan analysis Exclusion : History prior cancer except curatively treat , evidence cancer currently ( provide chemotherapy complete &gt; 6 month prior and/or bone marrow transplant &gt; 2 year prior first dose rucaparib ) . Prior treatment PARP inhibitor Symptomatic and/or untreated central nervous system metastases Preexisting duodenal stent and/or gastrointestinal disorder defect would , opinion Investigator , interfere absorption rucaparib Hospitalization bowel obstruction within 3 month prior enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cancer</keyword>
	<keyword>peritoneal cancer</keyword>
	<keyword>platinum sensitive</keyword>
	<keyword>relapse disease</keyword>
	<keyword>PARP Inhibitor</keyword>
	<keyword>rucaparib</keyword>
	<keyword>homologous recombination</keyword>
	<keyword>homologous recombination deficiency</keyword>
	<keyword>genomic scarring</keyword>
	<keyword>loss heterozygosity</keyword>
	<keyword>CO-338</keyword>
	<keyword>PF 01367338</keyword>
	<keyword>AG 14699</keyword>
	<keyword>platinum sensitive ovarian cancer</keyword>
	<keyword>platinum sensitive fallopian tube cancer</keyword>
	<keyword>platinum sensitive primary peritoneal cancer</keyword>
	<keyword>platinum sensitive peritoneal cancer</keyword>
	<keyword>gynecological cancer</keyword>
	<keyword>Clovis</keyword>
	<keyword>Clovis Oncology</keyword>
	<keyword>ARIEL2</keyword>
	<keyword>ARIEL 2</keyword>
	<keyword>ARIEL3</keyword>
	<keyword>ARIEL 3</keyword>
</DOC>